Literature DB >> 11053221

Chronic, but not acute, dosing of antipsychotic drugs alters neurotensin binding in rat brain regions.

P E Holtom1, P L Needham, G W Bennett, S Aspley.   

Abstract

The present study compared high affinity neurotensin (NT) binding in rat brain following acute or chronic treatment with the classical antipsychotic, haloperidol, and the newer antipsychotic drugs, clozapine and zotepine. Drugs were given orally, as an acute treatment (1 dose) or chronically (21 day dosing) and binding to the NT high affinity receptor was examined in three brain regions; striatum, nucleus accumbens/olfactory tubercle and frontal cortex. Acute dosing with either vehicle, haloperidol, clozapine or zotepine produced no significant changes in NT binding from controls (naïve rats). Chronic (21 day) dosing resulted in an increase in the K:(D:) and B(max) of high affinity receptors in the striatum following haloperidol, but not clozapine, zotepine or vehicles. In contrast, the newer antipsychotics, clozapine and zotepine but not haloperidol or vehicles, significantly altered NT binding in the nucleus accumbens/olfactory tubercle by decreasing the K:(D:) and B(max). Further differentiation between the two newer antipsychotic drugs occurred in the frontal cortex. Clozapine had no significant effect on NT binding, whereas zotepine significantly reduced the K:(D:) of the high affinity receptor with no alteration in B(max). The antipsychotic drugs tested did not interact directly with the NT high affinity receptor. Therefore, they must be acting indirectly via an alternative receptor mechanism to alter NT high affinity binding. In accordance with previously reported NT/dopamine receptor interactions, this would suggest cross-talk between these systems. Overall, these data demonstrate that chronic, but not acute, administration of antipsychotic drugs alters NT binding in the rat brain. In addition, anatomical differences in NT binding arise according to the antipsychotic drug under test. This may be predictive of drug side-effect profile, antipsychotic efficacy or atypicality.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11053221      PMCID: PMC1572411          DOI: 10.1038/sj.bjp.0703653

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  56 in total

1.  Dopaminergic control of 125I-labeled neurotensin binding site density in corticolimbic structures of the rat brain.

Authors:  D Herve; J P Tassin; J M Studler; C Dana; P Kitabgi; J P Vincent; J Glowinski; W Rostene
Journal:  Proc Natl Acad Sci U S A       Date:  1986-08       Impact factor: 11.205

2.  Effects of neurotensin on dopamine release and metabolism in the rat striatum and nucleus accumbens: cross-validation using in vivo voltammetry and microdialysis.

Authors:  C D Blaha; A Coury; H C Fibiger; A G Phillips
Journal:  Neuroscience       Date:  1990       Impact factor: 3.590

3.  The effects of chronic neuroleptic treatment on neurotensin-like immunoreactivity in the rat central nervous system.

Authors:  M Goedert; S D Iversen; P C Emson
Journal:  Brain Res       Date:  1985-06-03       Impact factor: 3.252

4.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

5.  c-fos antisense oligonucleotide specifically attenuates haloperidol-induced increases in neurotensin/neuromedin N mRNA expression in rat dorsal striatum.

Authors:  K M Merchant
Journal:  Mol Cell Neurosci       Date:  1994-08       Impact factor: 4.314

6.  Blockade of neurotensin receptor by SR 48692 potentiates the facilitatory effect of haloperidol on the evoked in vivo dopamine release in the rat nucleus accumbens.

Authors:  P Brun; R Steinberg; G Le Fur; P Soubrié
Journal:  J Neurochem       Date:  1995-05       Impact factor: 5.372

7.  Reduced CSF neurotensin concentration in drug-free schizophrenic patients.

Authors:  L H Lindström; E Widerlöv; G Bisette; C Nemeroff
Journal:  Schizophr Res       Date:  1988 Jan-Feb       Impact factor: 4.939

8.  CSF concentrations of neurotensin in schizophrenia: an investigation of clinical and biochemical correlates.

Authors:  N A Breslin; R L Suddath; G Bissette; C B Nemeroff; P Lowrimore; D R Weinberger
Journal:  Schizophr Res       Date:  1994-04       Impact factor: 4.939

9.  Neurotensin and cholecystokinin octapeptide control synergistically dopamine release and dopamine D2 receptor affinity in rat neostriatum.

Authors:  S Tanganelli; X M Li; L Ferraro; G Von Euler; W T O'Connor; C Bianchi; L Beani; K Fuxe
Journal:  Eur J Pharmacol       Date:  1993-01-12       Impact factor: 4.432

10.  Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs.

Authors:  B Gallhofer; U Bauer; S Lis; S Krieger; H Gruppe
Journal:  Eur Neuropsychopharmacol       Date:  1996       Impact factor: 4.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.